NCT03170206 2026-02-12
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
19 trialsNCT02285439 2025-10-07
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
Phase 1/2 Completed
NCT02185690 2025-08-21
MEK162
University Health Network, Toronto
Phase 1 Completed
NCT03106415 2025-06-27
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Mayo Clinic
Phase 1/2 Completed
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT04735068 2025-04-01
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT03475004 2024-09-19
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT03981614 2024-08-22
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT02613650 2024-08-09
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
University of Utah
Phase 1 Completed
NCT02631447 2024-06-07
SECOMBIT
Fondazione Melanoma Onlus
Phase 2 Completed
NCT02834364 2023-11-24
GMMG-BIRMA
University of Heidelberg Medical Center
Phase 2 Completed
NCT01859026 2023-01-19
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02964689 2021-07-14
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Swiss Cancer Institute
Phase 1 Completed
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT03158103 2021-04-30
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02902042 2021-02-16
IMMU-TARGET
University Hospital, Essen
Phase 1/2 Completed
NCT02773459 2019-09-30
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 1/2 Completed
NCT02041481 2018-01-25
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed